Special Communication
April 2022: Changes to CTELO, MECDS9, and K2 Testing
All changes effective May 16, 2022.
Changes to Reference Ranges
C Telopeptide, Beta Cross Linked (CTELO)
Male
6 months – 29 years:
238-1019 pg/mL
30-39 years:
225-936 pg/mL
40-49 years:
182-801 pg/mL
50-59 years:
161-737 pg/mL
60-69 years:
132-752 pg/mL
70 years or greater:
118-776 pg/mL
Female
Premenopausal:
136-689 pg/mL
Postmenopausal:
177-1015 pg/mL
Changes to Test Build
Synthetic Cannabinoid Metabolites – Expanded, Urine (Qualitative) (K2)
Change Overview:
9 components have been removed
Components to be Reported:
5-fluoro-PINACA 3-methylbutanoic acid
4-fluoro-BINACA 3,3-dimethylbutanoic acid
5-fluoro-PICA 3,3-dimethylbutanoic acid
5-fluoro-PINACA3,3-dimethylbutanoic acid
MDMB-4en-PINACA butanoic acid
FUBINACA 3-methylbutanoic acid
FUBINACA 3,3-dimethylbutanoic acid
4-carboxy-NA-PIM
Test Discontinuations
Meconium Drug Screen 9 (MECDS9)
Reason for Discontinuation:
Vendor test discontinuation
Alternative Test:
Drug Detection Panel, Meconium, Qualitative (MECDRG) – Available 05/16/22